After the COVID-19 pandemic had broken out, dermatologists were concerned about the safety of biologic treatment in psoriatic patients, hence more susceptible to infections. 1,2 However, there is some evidence of discrete COVID-19 symptoms and a rapid recovery in patients receiving guselkumab (anti-interluekin [IL]-23) and ixekizumab (anti-IL-17). 3,4 Moreover, Conti et al reported how elderly psoriatic patients receiving secukinumab (anti-IL-17) and adalimumab (antitumor necrosis factor alpha [anti-TNFα]) were completely unreceptive to COVID-19. 5 As CONFLICT OF INTEREST The authors declare no potential conflict of interest.

Treatment of psoriasis and psoriatic arthritis, especially moderate and severe, represents difficulties. Recently, various methods of molecular medicine have been actively developed, however, targeted therapy deserves special attention, which consists of chemical agents that have specific target as a specific protein or enzyme. Targeted therapy is a promising direction in many branches of medicine, especially in dermatology.Despite the wide range of biological products, their use may be accompanied by an increased risk of infectious processes and malignant neoplasms, which makes the search for a new pharmacological solution in targeted therapy even more relevant.This review presents the possibilities and prospects for the therapeutic use of the phosphodiesterase-4 inhibitor from the group of small molecules — apremilast, primarily in the treatment of psoriasis and psoriatic arthritis.

No abstract

Objective. to determine the effectiveness and tolerability of narrowband ultraviolet (UV) B (311 nm) plus an inhibitor of phosphodiesterase 4 (PDE4) combined therapy in patients with moderate to severe plaque psoriasis. Material and methods. the first group consisted of 30 patients (18 women and 12 men) who were treated with UVB 311 nm and inhibitor of phosphodiesterase 4 (PDE4). The second (control) group was treated with UVB 311 nm and methotrexate (n = 30; 15 women and 15 men). The study participants were aged 32 to 67 (43.8 ± 4.34). Results. it was determined greater efficiency (PASI 100 43.3% of patients and PASI 90 46.7%) of the treatment plaque moderate to severe psoriasis patients with UVB 311 nm plus an inhibitor of PDE4 compared to UVB 311 nm plus methotrexate (PASI 100 10% of patients and PASI 90 40%). The treatment was well-tolerated. The side effects in both groups were mild, did not require the cancellation of the prescribed treatment regimen, and were often stopped on their own or with minimal corrective therapy.